Caredx, Inc.
A precision medicine company focused on keeping transplanted organs healthy. CareDx makes non-invasive blood tests — AlloMap Heart and the AlloSure Kidney, Heart, and Lung panels — that monitor transplant recipients for early signs of rejection without a biopsy, along with HLA typing kits and AlloSeq gene-sequencing tools used to match donors and recipients. Its Ottr and MedActionPlan software help transplant teams track and manage patient care between visits.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Baron Capital Group, Inc. | 13G/APassive | 3.75% | 1.94M | Aug 14, 2026 |
| Ronald Baron | 13G/APassive | 3.75% | 1.94M | Aug 14, 2026 |
| BAMCO INC /NY/ | 13G/APassive | 3.22% | 1.66M | Aug 14, 2026 |
| Baron Capital Management, Inc. | 13G/APassive | 0.53% | 274.4K | Aug 14, 2026 |
| STATE STREET CORPORATION | 13GPassive | 4.8% | 2.47M | Aug 7, 2026 |
| Neil Gagnon | 13G/APassive | 4.4% | 2.29M | Aug 7, 2026 |
| Gagnon Securities LLC | 13G/APassive | 3.2% | 1.63M | Aug 7, 2026 |
| Gagnon Advisors, LLC | 13G/APassive | 0.8% | 408.8K | Aug 7, 2026 |
| BlackRock, Inc. | 13G/APassive | 9% | 4.66M | Jul 27, 2026 |
| The Vanguard Group | 13G/APassive | 0% | 0 | Mar 26, 2026 |